Eloralintide 10mg Dosage & Mixing Guide

What is Eloralintide?

Eloralintide — research code LY3841136 — is a long-acting, selective amylin receptor agonist developed by Eli Lilly for weight-management research. It is a 37-amino-acid peptide carrying three non-coded residues and a C20 fatty diacid at Lys26, which binds albumin and gives the molecule its very long duration of action.

The word doing the work is selective. In human receptor assays eloralintide is roughly 12x more potent at AMY1R than at the calcitonin receptor and about 11x more potent at AMY1R than at AMY3R. Cagrilintide, by contrast, engages amylin and calcitonin receptors together. That difference in selectivity is the design premise behind the whole programme.

Activating amylin receptors promotes satiety, slows gastric emptying and reduces food intake — mechanisms that sit alongside GLP-1 signalling rather than duplicating it.

The 10mg vial is the one that suits the full trial dose range. The Phase 2 programme ran to 9mg weekly, and at this vial’s concentration a 9mg dose is still a single 90-unit draw.

Quick Reference

Why 1mL? At 10mg/mL every dose in the studied range, right up to 9mg, fits inside one U-100 syringe. Adding more water pushes the higher doses past the 100-unit mark and forces a second draw.

Reconstitution Guide

Materials Needed

• Eloralintide 10mg lyophilized vial
• Bacteriostatic water (BAC water)
• Insulin syringes (U-100, 29-31 gauge)
• Alcohol swabs
• Sharps container

Step-by-Step Instructions

1. Prepare your workspace — Clean your work area and gather all materials. Wash hands thoroughly.

2. Clean the vial stoppers — Wipe the Eloralintide vial stopper and BAC water vial with alcohol swabs. Allow to dry completely.

3. Draw the BAC water — Using a sterile syringe, draw 1mL of bacteriostatic water.

4. Add water to peptide vial — Insert the needle into the Eloralintide vial and slowly inject the BAC water down the inside wall of the vial. Do not spray directly onto the powder.

5. Allow to dissolve — Give it 5-10 minutes to dissolve fully. Gently swirl occasionally — never shake vigorously.

6. Verify dissolution — The solution should be completely clear and colorless. If cloudy or particles remain, continue gentle swirling.

7. Label and store — Write the reconstitution date on the vial. Store in refrigerator immediately.

Dosage Protocol

Concentration Calculations

With 10mg peptide in 1mL BAC water:

• Concentration: 10mg/mL = 10000mcg/mL
• Per unit (U-100 syringe): 100mcg per unit

The arithmetic here is unusually friendly: at this concentration, units equal dose in units of 0.1mg. A 3mg dose is 30 units, a 9mg dose is 90 units.

Common Dose Calculations

Suggested Titration Protocol

The Phase 2 trial ran fixed arms at 1, 3, 6 and 9mg, and also tested two escalation regimens. This ladder mirrors its 3/6/9 escalation:

Important Notes:

• Hold each level at least 4 weeks before escalating
• The trial’s escalation arms did not outperform going straight to a fixed 9mg (-19.9% escalated vs -20.1% fixed), so escalation is about tolerance, not outcome
• A 10mg vial at 9mg weekly yields one full dose and a remainder — plan vial count accordingly

Injection Guide

Subcutaneous Administration

1. Clean the injection site with an alcohol swab
2. Pinch a fold of skin (abdomen, thigh, or upper arm)
3. Insert needle at 90° angle for most body types
4. Inject slowly and steadily
5. Wait 5-10 seconds before withdrawing needle
6. Apply light pressure if needed — do not rub

Site Rotation

Rotate between these areas weekly:

• Abdomen (2+ inches from navel) — most common
• Outer thigh (front/outer area)
• Back of upper arm

Consistency tip: Administer on the same day each week. With a half-life this long, timing drift matters less than with most peptides — but a fixed day keeps the record clean.

Storage Requirements

Lyophilized (Powder Form)

• Temperature: -20°C or colder
• Duration: 2+ years
• Conditions: Protect from light and moisture

Reconstituted (Mixed with BAC Water)

• Temperature: 2-8°C — standard refrigerator
• Duration: 4-6 weeks
• Conditions: Keep away from light, never freeze reconstituted solution

Important Storage Notes

• Minimize time outside refrigeration once reconstituted
• Do not use if solution becomes cloudy, discolored, or contains particles
• Keep track of reconstitution date and discard after 6 weeks maximum

Research Considerations

Half-Life and Accumulation

Phase 1 measured a half-life of 310-366 hours (roughly 13-15 days) across single subcutaneous doses from 0.4mg to 12mg. That is notably longer than cagrilintide’s ~7-8 days and is the basis for once-weekly dosing.

It also has a practical consequence. When the dosing interval is much shorter than the half-life, levels accumulate: dosing weekly at a ~2-week half-life means each dose lands while most of the previous one is still present. Steady state takes several weeks to arrive, and a dose change takes just as long to fully express — which is exactly why the trial held each escalation step for four weeks.

Key Research Findings

The 48-week Phase 2 trial (263 participants, mean baseline weight 109.1kg) reported:

Eloralintide has since moved into a broad Phase 3 programme covering obesity, obesity with type 2 diabetes, knee osteoarthritis and obstructive sleep apnoea, plus Phase 2 combination work alongside incretins.

Safety & Handling

General Precautions

• Use sterile technique for all preparations
• Never reuse needles or syringes
• Dispose of sharps properly in designated containers
• Store away from children and unauthorized persons

Research Considerations

• Eloralintide is for research purposes only
• Eloralintide is not an approved medicine — it is investigational and still in trials
• Research-grade peptides are not equivalent to pharmaceutical preparations
• Follow institutional guidelines for peptide research

Sourcing for Research

Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.

Scientific References

1. Roell WC, et al. “Discovery and characterization of eloralintide, a selective amylin receptor agonist.” Pharmacology & Translational Science. 2025.
2. “Eloralintide demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight.” Eli Lilly. 2025.
3. Phase 2 dose-finding trial NCT06230523, ClinicalTrials.gov.

Last updated: July 16, 2026

Disclaimer: This information is for educational and research purposes only. Eloralintide as a research peptide is not intended for human consumption. Eloralintide is not an approved medicine. Always follow applicable laws and institutional guidelines.